Skip to main content

Immuron Director resignation

Written by Customer Service on . Posted in Public Companies.

MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation of Mr Peter Anastasiou.

Mr Anastasiou joined the Board in May 2015 after becoming a major shareholder in 2013 and was appointed Vice Executive Chairman in August 2015 to assist US market development opportunities and supporting key programs at Immuron.

Mr Anastasiou commented that “Small companies rarely get an opportunity to acquire a transformative asset of national significance. Our shareholders have lost a chance to contribute to the advancement of very safe Covid vaccine. As a result, I have decided to step down despite my confidence in Immuron technology and the strong financial position the company is in.”

The Board is enormously grateful to Peter for all of his hard work, energy and expertise over the last few years. He has made a significant contribution in securing Immuron’s long term future and leaves the Company in a substantially significantly stronger position than when he joined the Board. The Company’s strong cash reserves and pipeline of exciting projects promise a bright future and we look forward to continuing our relationship with Peter in his capacity as a significant Shareholder.

This release has been authorised by directors of Immuron Limited.

COMPANY CONTACT:

Dr Jerry Kanellos, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com

  

For more information visit: http://www.immuron.com

 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.